Evidence map›Paper›PMID 27549371›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2016

Higher Order Chromatin Modulator Cohesin SA1 Is an Early Biomarker for Colon Carcinogenesis: Race-Specific Implications.

Ramesh K Wali, Navneet Momi, Mart Dela Cruz, Audrey H Calderwood, Yolanda Stypula-Cyrus, Luay Almassalha, Anuj Chhaparia, Christopher R Weber, Andrew Radosevich, Ashish K Tiwari and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ramesh K WaliDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts.
Navneet MomiDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts.
Mart Dela CruzDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts.
Audrey H CalderwoodDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts.
Yolanda Stypula-CyrusDepartment of Biomedical Engineering, Northwestern University, Evanston, Illinois.
Luay AlmassalhaDepartment of Biomedical Engineering, Northwestern University, Evanston, Illinois.
Anuj ChhapariaDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts.
Christopher R WeberDepartment of Pathology, University of Chicago, Illinois.
Andrew RadosevichDepartment of Biomedical Engineering, Northwestern University, Evanston, Illinois.
Ashish K TiwariDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts.
Bilal LatifDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts.
Vadim BackmanDepartment of Biomedical Engineering, Northwestern University, Evanston, Illinois.
Hemant K RoyDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts. hkroy@bu.edu.
Northwestern University · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Training Program In Lung SciencesT32HL076139 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KAREN M RIDGE, Jacob I Sznajder · 2004 to 2026
$9.6M
Biophotonics to Couple Pancreatic with Upper GI Screening via Ultrathin EndoscopyR01CA183101 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, ROGERS, JEREMY D. · 2015 to 2019
$3.2M
Risk-stratification of Prostate Cancers via Field Carcinogenesis NanocytologyR01CA200064 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, CRAWFORD, SUSAN E. · 2015 to 2019
$3.1M
Nanoscale/Molecular analysis of Fecal Colonocytes for Colorectal Cancer ScreeningR01CA165309 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, ROY, HEMANT K. · 2012 to 2016
$2.8M
Transforming Colorectal Cancer Screening through Multimodal Spectral MarkersR01CA156186 · NCI · ENDEAVOR HEALTH CLINICAL OPERATIONS · PI BACKMAN, VADIM, ROY, HEMANT K. · 2011 to 2015
$2.8M
Towards Development of an in vitro Assay to Personalize Colonic ChemopreventionR03CA195143 · NCI · BOSTON MEDICAL CENTER · PI ROY, HEMANT K. · 2015 to 2016
$174k
NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA156186NCI NIH HHS R01 CA165309NCI NIH HHS R01 CA183101NCI NIH HHS R01 CA200064NCI NIH HHS R03 CA195143NHLBI NIH HHS T32 HL076139
6 · The paper itself

Abstract

Alterations in high order chromatin, with concomitant modulation in gene expression, are one of the earliest events in the development of colorectal cancer. Cohesins are a family of proteins that modulate high-order chromatin, although the role in colorectal cancer remains incompletely understood. We, therefore, assessed the role of cohesin SA1 in colorectal cancer biology and as a biomarker focusing in particular on the increased incidence/mortality of colorectal cancer among African-Americans. Immunohistochemistry on tissue arrays revealed dramatically decreased SA1 expression in both adenomas (62%; P = 0.001) and adenocarcinomas (75%; P = 0.0001). RT-PCR performed in endoscopically normal rectal biopsies (n = 78) revealed a profound decrease in SA1 expression in adenoma-harboring patients (field carcinogenesis) compared with those who were neoplasia-free (47%; P = 0.03). From a racial perspective, colorectal cancer tissues from Caucasians had 56% higher SA1 expression than in African-Americans. This was mirrored in field carcinogenesis where healthy Caucasians expressed more SA1 at baseline compared with matched African-American subjects (73%; P = 0.003). However, as a biomarker for colorectal cancer risk, the diagnostic performance as assessed by area under ROC curve was greater in African-Americans (AUROC = 0.724) than in Caucasians (AUROC = 0.585). From a biologic perspective, SA1 modulation of high-order chromatin was demonstrated with both biophotonic (nanocytology) and chromatin accessibility [micrococcal nuclease (MNase)] assays in SA1-knockdown HT29 colorectal cancer cells. The functional consequences were underscored by increased proliferation (WST-1; P = 0.0002, colony formation; P = 0.001) in the SA1-knockdown HT29 cells. These results provide the first evidence indicating a tumor suppressor role of SA1 in early colon carcinogenesis and as a risk stratification biomarker giving potential insights into biologic basis of racial disparities in colorectal cancer. Cancer Prev Res; 9(11); 844-54. ©2016 AACR.

Indexed as

AdenocarcinomaAdenomaBiomarkers, TumorBlack or African AmericanCarcinogenesisChromatinColonic NeoplasmsFemaleHumansIncidenceMaleMiddle AgedNuclear ProteinsWhite PeopleBiomarkers, TumorChromatinNuclear ProteinsPDS5A protein, human

Identifiers

PMID27549371
PMCPMC5093027
OpenAlexW2509066349

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.